7Baggers

We provide you with 20 years of free, institutional-grade data for FULC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of FULC. Explore the full financial landscape of FULC stock.

Reported DateCIKTickerType
2024-02-270001680581FULC10-KUrl
2023-11-070001680581FULC10-QUrl
2023-08-030001680581FULC10-QUrl
2023-05-150001680581FULC10-QUrl
2023-03-090001680581FULC10-KUrl
2022-11-080001680581FULC10-QUrl
2022-08-110001680581FULC10-QUrl
2022-05-090001680581FULC10-QUrl
2022-03-030001680581FULC10-KUrl
2021-11-040001680581FULC10-QUrl
2021-08-100001680581FULC10-QUrl
2021-05-060001680581FULC10-QUrl
2021-03-040001680581FULC10-KUrl
2020-11-100001680581FULC10-QUrl
2020-08-110001680581FULC10-QUrl
2020-06-220001680581FULCS-1Url
2020-05-130001680581FULC10-QUrl
2020-03-050001680581FULC10-KUrl
2019-11-140001680581FULC10-QUrl
2019-08-260001680581FULC10-QUrl
2019-06-210001680581FULCS-1Url

Fulcrum Therapeutics, Inc
(NASDAQ:FULC) 

FULC stock logo

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is i...

Founded: 2015
Full Time Employees: 73
CEO: Robert J. Gould  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about FULC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.